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1. Patients with ANCA-associated vasculitis who are treated with rituximab have a decreased burden of 
malignancy, which surpasses expectations from clinical trials data.
(this thesis)
2. Patients with anti-glomerular basement membrane disease who are dialysis dependent at presentation 
and have either ≥50% globally sclerotic glomeruli or 100% cellular crescents do not benefit from 
intensive therapy and could therefore be protected against the risk of immunosuppression by 
following a conservative regimen.
(this thesis)
3. With respect to prognostic value, the crescentic and mixed classes of the histopathological classification 
for ANCA-associated glomerulonephritis can be considered similar.
(this thesis)
4. Changes in podocyte morphology in patients with ANCA-associated glomerulonephritis are indicative 
of whether or not patients will have an increase of proteinuria at short-term follow-up.
(this thesis)
5. Given that the current standard of care of ANCA-associated vasculitis is to use rituximab during the 
induction treatment phase, clinicians can be reassured that rituximab is not only efficacious (…), but 
also safer - at least during the first five to six years post-treatment.
(Dr. D. Ang, MD Alert newsfeed, 2016)
6. Nowadays, a higher proportion of vasculitis patients may be treated at an earlier stage of the disease 
and less severe cases are diagnosed, compared with the pre-ANCA era.
(Eriksson et al. J Intern Med 265: 496-506, 2009)
7. The question of prognosis in patients with glomerulonephritis is one of the most common questions 
that patients ask clinicians. 
(Hogan et al. J Am Soc Nephrol 7: 23-32, 1996)
8. Randomized, controlled trials conducted in the last 15 years in ANCA-associated vasculitis provide 
important prospective data on the adverse effects of medications, allowing physicians and patients 
to consider an individualized risk/benefit ratio for each patient, a luxury that was not available when 
cyclophosphamide plus steroids was the only recommended treatment. 
(Hogan et al. Clin J Am Soc Nephrol 9: 1657-1667, 2014)
9. There’s trials and there’s the truth.
(Prof. D. Jayne, 18th International Vasculitis and ANCA Workshop, 2017)
Although there is definitely much to learn from clinical trials, we should not recognize them as the truth. Every 
study result requires validation, also in a non-trial setting.
10. To expect the unexpected shows a thoroughly modern intellect.
(Oscar Wilde, An ideal Husband, 1893)
Lives do not always unfold as previously planned and the same accounts for research projects. A modern 
intellect should have the ability to adapt to unexpected situations; a skill which I have started to develop 
throughout my PhD project. 
11. De wetenschappelijke wereld moet het antwoord op vele vragen nog steeds schuldig blijven en met 
voortschrijdend inzicht komen nieuwe vragen. 
thesis A.E. Berden, ANCA-associated vasculitis: towards patient-tailored therapy, 2011)
In mijn proefschrift blijven veel vragen nog open, maar hopelijk draagt mijn onderzoek bij aan het oplossen 
van de puzzel die vasculitis heet.
